



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

16 December 2025  
EMA/394227/2025  
Human Medicines Division

## Overview of (invented) names reviewed in November 2025 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 11 December 2025

	NRG meeting 11-12 February		NRG meeting 8-9 April		NRG meeting 11-12 June		NRG meeting 23-24 September		NRG meeting 18-19 November		2025 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names	47	38	56	35	31	33	56	45	83	39	<b>273</b>	<b>190</b>
Proposed INN+MAH/TM names	1	0	1	0	2	0	2	0	8	0	<b>14</b>	<b>0</b>
Re-use/re-confirmation applications	2	0	0	0	3	1	0	0	4	0	<b>9</b>	<b>1</b>
Justification for retention of (invented) name *	3	3	4	0	1	5	2	6	4	2	<b>14</b>	<b>16</b>

\*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



	NRG meeting 11-12 February		NRG meeting 8-9 April		NRG meeting 11-12 June		NRG meeting 23-24 September		NRG meeting 18-19 November		2025 total	
	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed
Total number of objections raised	78	163	65	139	72	139	94	170	130	145	<b>439</b>	<b>756</b>
Similarity with other (invented) name	49	143	48	113	46	113	62	135	55	165	<b>212</b>	<b>556</b>
Conveys misleading therapeutic connotations	4	2	0	0	1	1	2	4	2	1	<b>9</b>	<b>8</b>
Conveys misleading pharmaceutical connotations	0	0	0	0	0	0	0	0	1	0	<b>1</b>	<b>0</b>
Similarity with INN	5	8	9	11	15	12	10	7	8	13	<b>47</b>	<b>51</b>
Inclusion of INN stem	1	1	0	0	0	0	1	0	0	0	<b>2</b>	<b>1</b>
Unacceptable qualifiers	1	1	0	0	0	0	0	0	0	0	<b>1</b>	<b>1</b>
Conveys a promotional message	8	4	1	8	4	3	5	15	3	12	<b>21</b>	<b>42</b>
Appears offensive or has an inappropriate connotation	0	0	4	1	3	0	2	0	4	0	<b>13</b>	<b>1</b>
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0	0	0	0	0	0	0	<b>0</b>	<b>0</b>
Similarity between name of prodrug and related active substance	0	0	0	0	0	0	0	0	0	0	<b>0</b>	<b>0</b>
Inclusion of common umbrella segment	0	0	0	0	0	0	0	0	0	0	<b>0</b>	<b>0</b>
Potential difficulties in pronunciation	6	1	3	1	2	3	7	1	3	1	<b>21</b>	<b>7</b>
Others	0	0	0	0	2	2	2	3	4	3	<b>8</b>	<b>8</b>

See [Guideline on the acceptability of names for human medicinal products processed through the centralised procedure \(EMA/CHMP/287710/2014 - Rev. 7\)](#) for detailed explanations of criteria used.